Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Experimental Chikungunya Vaccine Induces Robust Antibody Response

Published: Saturday, August 16, 2014
Last Updated: Saturday, August 16, 2014
Bookmark and Share
Vaccine developed by NIH scientists performs well in early clinical trial.

An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results are reported in the current issue of The Lancet.

The most distinctive symptom of chikungunya infection is severe joint pain accompanied by headache and fever. There are currently no vaccines or specific drug treatments for chikungunya. First identified in East Africa in the early 1950s, chikungunya virus caused sporadic illness in Africa and large urban outbreaks in Thailand and India in the 1960s and 1970s. It first appeared in the Western Hemisphere in late 2013.

As of August 8, more than 570,000 confirmed or suspected cases had been reported throughout the Americas. In the continental United States, 484 cases have been reported as of August 5, and the first two locally acquired infections were detected in Florida in mid-July.

"The two species of mosquito that spread chikungunya virus are found in parts of the continental United States, so it may just be a matter of time before this illness gains a foothold here," said NIAID Director Anthony S. Fauci, M.D. "Therefore, it is prudent to begin addressing this emerging public health threat with the development of vaccines, such as this one, which was designed and tested by scientists from the NIAID Vaccine Research Center."

In 2010, Vaccine Research Center (VRC) scientists and colleagues tested this candidate chikungunya vaccine in non-human primates. All of the immunized animals were protected from infection when later exposed to chikungunya virus.

In the newly reported trial, 23 healthy volunteers received three injections (two other volunteers received two injections) of vaccine at one of three different dosages (10, 20 or 40 micrograms) over a 20-week span. Antibody production was measured at multiple time points following each injection.

Investigators detected chikungunya neutralizing antibodies in all volunteers following the second injection, with a significant boost of neutralizing antibodies seen following the third injection. Vaccine-induced antibodies persisted in all volunteers, even those who received the lowest dosage, for at least 11 months after the final vaccination, suggesting that the vaccine could provide durable protection against disease.

"The candidate vaccine prompted a robust immunological response in recipients and was very well tolerated," noted VRC scientist Julie E. Ledgerwood, D.O., principal investigator of the trial. "Notably, the levels of neutralizing antibody produced in response to the experimental vaccine were comparable to those seen in two patients who had recovered from a chikungunya virus infection acquired elsewhere. This observation gives us additional confidence that this vaccine would provide as much protection as natural infection."

Whereas traditional vaccines are typically made from either killed viruses or from weakened live viruses, the experimental vaccine used in the trial is a different type: a virus-like particle (VLP) vaccine. VLP vaccines contain the outer shell proteins of a virus without any of the material the virus needs to replicate inside cells. VLP vaccines often prompt an immune reaction similar to that of natural, whole virus and have a number of potential advantages over traditional vaccines, said Dr. Ledgerwood. Notably, because no live viruses are used in their manufacture, VLP vaccines do not need to be produced under high-level biocontainment conditions.

This candidate vaccine was delivered without an adjuvant - a substance added to vaccines to improve the immune response - but still prompted a good response, said Dr. Ledgerwood. If the candidate were to be formulated with an adjuvant, she added, it might be possible to achieve similar immune responses at lower vaccine dosages.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Wednesday, November 30, 2016
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Monday, November 21, 2016
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Tuesday, November 08, 2016
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Wednesday, October 26, 2016
Sustained SIV Remission Achieved in Monkeys
Experimental treatment boosts monkey immune system to force SIV into sustained remission.
Wednesday, October 26, 2016
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Wednesday, October 05, 2016
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
Thursday, September 29, 2016
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Tuesday, August 09, 2016
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Thursday, August 04, 2016
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Friday, July 29, 2016
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Thursday, July 28, 2016
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Monday, July 25, 2016
NIH Investment Into HIV Research Expands
Funding has been awarded to six research teams to lead collaborative investigations worldwide toward an HIV cure.
Thursday, July 14, 2016
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
Wednesday, May 18, 2016
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Tuesday, May 17, 2016
Scientific News
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!